Join
Live feed
·
PRReleasevia Quantisnow
Blueprint Medicines Corporation logo

Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints

ByQuantisnow·Wall Street's wire, on your screen.
BPMC· Blueprint Medicines Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BPMC (Blueprint Medicines Corporation) and more on Quantisnow.